Miruvor
Sign up
The short answer

What studies of astragalus found

3papers on astragalus
32people in 1 study testing astragalus alone
1randomised trial, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, the placebo trial (very low certainty), for fatigue.

1 outcome rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Astragalus might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 3 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Astragalus · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Fatigue1 study · 32 people took astragalus Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (64 in all).

The placebo trial64 randomised · at the end of and 1 month after the intervention · 500 mg, two times per day

Fatigue improved more than in the comparison group.

The evidence is very uncertain about the effect of astragalus on fatigue in long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (64 in all)
See the 1 study
  1. Chronic fatigue syndrome post-COVID-19: triple-blind randomised clinical trial of Astragalus root extract. (2025)

    People in the study
    64 randomised
    Dose
    500 mg, two times per day
    Outcome
    risk of chronic fatigue
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Studies of combinations

Outcomes that only studies of astragalus given together with other treatments looked at. Shown, not graded: they can’t tell what astragalus did alone.

Daily functioning ME/CFS

Combination: Levothyroxine (Synthroid) + Natural desiccated thyroid (Armour, NP Thyroid) + Doxycycline (Vibramycin) + Nystatin + a different antibiotic + Succinic acid + NAC (N-acetylcysteine) + Bromelain + a liver detox blend + Antibiotics (unspecified) + Gentamicin + Hydroxychloroquine / Plaquenil + Dipyridamole (Persantine) + Lactoferrin and colostrum + Astragalus + Andrographis + AHCC and medicinal mushrooms (reishi, shiitake, maitake) + Fluconazole (Diflucan) + Kelp + Ashwagandha + Eleuthero (Siberian ginseng) + Licorice and glycyrrhizin + Fludrocortisone / Florinef + Trauma work (EFT, EMDR, TRE) + light therapy + Inosine + PABA (para-aminobenzoic acid) + DMAE + Lyme / co-infection protocols + Colloidal silver + Olive leaf extract + Antimicrobial botanicals (other) + Neem1 in the study

Chronic Fatigue Syndrome: A Case Report Highlighting Diagnosing and Treatment Challenges and the Possibility of Jarisch-Herxheimer Reactions If High Infectious Loads Are Present. (2021): return to graduate school, better (not tested).

Shown, not counted: astragalus was given together with other treatments.

Cognition (brain fog) ME/CFS

Combination: Levothyroxine (Synthroid) + Natural desiccated thyroid (Armour, NP Thyroid) + Doxycycline (Vibramycin) + Nystatin + a different antibiotic + Succinic acid + NAC (N-acetylcysteine) + Bromelain + a liver detox blend + Antibiotics (unspecified) + Gentamicin + Hydroxychloroquine / Plaquenil + Dipyridamole (Persantine) + Lactoferrin and colostrum + Astragalus + Andrographis + AHCC and medicinal mushrooms (reishi, shiitake, maitake) + Fluconazole (Diflucan) + Kelp + Ashwagandha + Eleuthero (Siberian ginseng) + Licorice and glycyrrhizin + Fludrocortisone / Florinef + Trauma work (EFT, EMDR, TRE) + light therapy + Inosine + PABA (para-aminobenzoic acid) + DMAE + Lyme / co-infection protocols + Colloidal silver + Olive leaf extract + Antimicrobial botanicals (other) + Neem1 in the study

Chronic Fatigue Syndrome: A Case Report Highlighting Diagnosing and Treatment Challenges and the Possibility of Jarisch-Herxheimer Reactions If High Infectious Loads Are Present. (2021): doing better cognitively, better (not tested).

Shown, not counted: astragalus was given together with other treatments.

Side effects

No study of this treatment alone reported side effects we could read.

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    500 mg at the start

  2. 2Top dose

    Most often 500 mg (1 of 1 studies)

Doses across 1 study

500 to 500 mg.

Each study’s dose, as printed

All papers

  1. Chronic fatigue syndrome post-COVID-19: triple-blind randomised clinical trial of Astragalus root extract.2025 · placebo trial · 64 randomised
    Summary

    This triple-blind randomised controlled trial, conducted in Iran in 2023, studied 64 nurses with post-COVID-19 chronic fatigue syndrome. Participants were randomly assigned to an intervention group (n=32) receiving Astragalus root extract 500 mg two times per day or a control group (n=32) receiving placebo. The duration of treatment was not reported; changes in chronic fatigue syndrome scores were measured before, at the end of, and 1 month after the intervention. In the intervention group, chronic fatigue prevalence decreased statistically significantly at the end of the intervention (13.8%) and 1 month later (17.2%); frequency differed between before and after (p=0.0001) and 1 month later (p=0.0001). In the control group, chronic fatigue was statistically significantly different before and after the intervention (72.2%; p=0.003). Being in the control group increased the risk of chronic fatigue (B=2.15, OR=12.36; p=0.01); having an underlying disease also increased risk (B=0.84, OR=2.33; p=0.04), while increasing the length of time decreased it (B=−0.67, OR=0.50; p=0.0001). The authors concluded: “Astragalus root extract has been shown to reduce chronic fatigue in nurses.” The paper did not report side effects, withdrawals in connection with harms, worsening, stopping, or the number analysed; limitations were not reported.

  2. Chronic Fatigue Syndrome: A Case Report Highlighting Diagnosing and Treatment Challenges and the Possibility of Jarisch-Herxheimer Reactions If High Infectious Loads Are Present.2021 · combination: given with other treatments · 1 in the study
    Summary

    This case report described one patient with severe ME/CFS who presented to a rheumatologist’s office in August 2013 after becoming bedridden 4.5 years earlier. Over a 4-year period from September 2013 to August 2017, the patient received a changing protocol that included thyroid medications, antibiotics, antifungals, Hydroxychloroquine, colostrum, kelp, licorice root, fludrocortisone, EFT, EMDR, light therapy, and multiple herbs and supplements. No comparison group was reported. The report described function and symptoms over time. By the Spring of 2014 (~6 months after onset of treatment), she had improved enough to take a college course 1 day/week but was not well enough to drive. By February 2015 she was still predominantly housebound; she was doing better cognitively, but simple activity like walking was still too difficult on most days. She was back at the gym by April 2017 and going for walks daily. In August 2017 she was well enough to move out from her parents’ home and resume graduate school, and she had been stable for at least 6 months. Reported harms included Jarisch–Herxheimer reactions with severe joint and musculoskeletal pain, worsening fatigue, worsening cognitive function, migraines, and drops in blood pressure; doxycycline was discontinued. She also had severe reactions from all supplements, severe discomfort during EFT/EMDR sessions, and could not tolerate blue light more than 1–2 min without severe migraines. The authors stated it was not possible to determine whether improvements were mediated by treatments or spontaneous remission/placebo.

  3. The Post-COVID syndrome caused by excessive inflammation: pathogenesis, potential targets and therapeutic agents.2026 · review
    Summary

    This review examined pharmacological interventions for post-COVID syndrome (PCS) predominantly characterised by persistent fatigue, with no participants of its own. It summarised studies of CoQ10 plus ALA, cacao flavonoids, amantadine, L-arginine plus vitamin C, fluvoxamine, astragalus root extract, Myelophil/MYPplus, Paxlovid, abrocitinib, upadacitinib, AXA1125, oxaloacetate, nicotinamide riboside, fexofenadine plus famotidine and IVIg. In a prospective observational study, 174 people with long COVID were enrolled and 116 received CoQ10 plus ALA; 53.5% had a complete FSS response versus 3.5% in the control group, and the non-response rate was 9.5% versus 25.9%. A cacao flavonoid trial (n = 46) reported improvements after 90 days. An open-label amantadine trial enrolled 83 patients; after 2 weeks scores were significantly superior to control (P < 0.001). A single-blind trial in 46 patients reported fatigue in 8.7% with L-arginine plus vitamin C versus 80.1% with placebo at day 28 (p < 0.0001). A fluvoxamine trial enrolled 399 patients and reduced FSS scores at day 60 and day 90; the fluvoxamine group had a lower incidence of adverse events, with rare serious adverse reactions. An astragalus trial reported chronic fatigue prevalence falling from 100% to 13.8%, and 17.2% one month later, versus 80.0% and 70.0% with placebo (P < 0.0001). A phase IIa AXA1125 trial found no overall differences in objective mitochondrial function between treatment and placebo. Amantadine was well tolerated with no notable safety concerns; astragalus had no obvious adverse reactions. Current evidence is mainly from observational studies or small-sample RCTs and is insufficient as definitive evidence of efficacy.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime